Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts [PDF]
, 2019 Despite recent progress in its treatment, Multiple Myeloma (MM) remains incurable and its associated bone disease persists even after complete remission.
Atkinson, Emily G. +7 more
core +1 more source
Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference [PDF]
, 2021 Somayya Noori +10 more
openalex +1 more source
Nature Reviews Disease PrimersMultiple myeloma (MM) is a haematological lymphoid malignancy involving tumoural plasma cells and is usually characterized by the presence of a monoclonal immunoglobulin protein. MM is the second most common haematological malignancy, with an increasing global incidence.
Florent Malard +7 more
openaire +3 more sources
Retinoic Acid Reprograms Mast Cells Toward a Proinflammatory State to Enhance Antitumor Immunity
Advanced Science, EarlyView.Proinflammatory mast cells represent an MHC‐IIhigh, cytokine‐producing mast cell subset associated with improved survival and enhanced responses to anti‐PD‐1 therapy. Retinoic acid drives their polarization, enabling antigen uptake and presentation, and T cell recruitment and activation, collectively promoting adaptive anti‐tumor immunity.
Lizao Zhang +25 more
wiley +1 more source
Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma
Nature CommunicationsAnti-CD38 monoclonal antibodies like Daratumumab (Dara) are effective in multiple myeloma (MM); however, drug resistance ultimately occurs and the mechanisms behind this are poorly understood.
Jiye Liu +21 more
doaj +1 more source
CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
Nature Communications, 2020 CD229 is expressed on the surface of multiple myeloma cells, as well as B and T lymphocytes. Here, the authors engineer CD229-specific CAR T cells and, using patient samples and mouse models, show that treatment with these cells reduces tumour burden and
Sabarinath V. Radhakrishnan +13 more
doaj +1 more source
Lactylation‐Driven YTHDC1 Alleviates MASLD by Suppressing PTPN22‐Mediated Dephosphorylation of NLRP3
Advanced Science, EarlyView.In MASLD, YTHDC1 undergoes increased lactylation and ubiquitination, reducing its expression. AARS1 mediates lactylation at lysine 565, while disrupted binding to LDHA further promotes lactylation, suppressing YTHDC1. This downregulation enhances PTPN22 mRNA stability, leading to NLRP3 dephosphorylation and activation, which exacerbates inflammation ...
Feng Zhang +16 more
wiley +1 more source
Advanced Science, EarlyView.This study shows that monocytes in multiple myeloma display an excessive interferon response, leading to transcriptional reprogramming and altered differentiation. Using single‐cell sequencing, coculture experiments, and patient samples before and after therapy, the authors demonstrate that induction treatment reduces this interferon response ...
Jian Cui +18 more
wiley +1 more source
Frontiers in Immunology, 2018 The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma (RRMM) was a critical advance for immunotherapies for multiple myeloma (MM ...
Shih-Feng Cho +7 more
doaj +1 more source
The RAG Model: a new paradigm for genetic risk stratification in multiple myeloma [PDF]
, 2014 Molecular studies have shown that multiple myeloma is a highly genetically heterogonous disease which may manifest itself as any number of diverse subtypes each with variable clinicopathological features and outcomes.
Chevassut, Timothy J +2 more
core +3 more sources